Piper Sandler Downgrades Halozyme Therapeutics to Neutral, Raises Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has downgraded Halozyme Therapeutics from Overweight to Neutral while raising the price target from $48 to $51.

June 07, 2024 | 9:20 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler downgraded Halozyme Therapeutics from Overweight to Neutral but raised the price target from $48 to $51.
The downgrade from Overweight to Neutral suggests a less bullish outlook on the stock, which could lead to a neutral or slightly negative short-term impact. However, the raised price target to $51 indicates some positive expectations, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100